The rAsp f3-based vaccine protects neutrophil-depleted mice. (A) Timeline of immunization, neutrophil depletion and A. fumigatus challenge. (B) FACS analysis of Ly6C+/GR1+ neutrophils in tail blood of rAsp f3-vaccinated mice after anti-GR1 antibody-mediated neutrophil depletion (left panel) compared to that of CA-immunosuppressed mice (right panel). (C) Kaplan–Meier survival curves of neutrophil-depleted mice challenged with 30 million viable conidia (VC) after mock vaccination with buffer and TiterMax (PBS-TM, triangles, n = 17) or rAsp f3-vaccine (rAsp f3, circles, n = 12), and non-immunosuppressed, non-vaccinated controls (Control, diamond, n = 12). (D) Survival of CA-immunosuppressed mice challenged with 30 million VC after rAsp f3-vaccination (rAsp f3, squares, n = 12) or mock vaccination (PBS-TM, triangles, n = 5). (E) CA-immunosuppressed mice challenged with three million VC, rAsp f3-vaccinated (circles, n = 28), or mock vaccinated (squares, n = 26).